Oramed Pharmaceuticals Inc. (TLV:ORMP)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 428.17M |
| Revenue (ttm) | 6.62M |
| Net Income | 145.20M +882.1% |
| EPS | 3.40 +838.2% |
| Shares Out | n/a |
| PE Ratio | 2.95 |
| Forward PE | n/a |
| Dividend | 0.79 (7.24%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 1,884 |
| Average Volume | 17,857 |
| Open | 1,064.00 |
| Previous Close | 1,064.00 |
| Day's Range | 1,055.00 - 1,066.00 |
| 52-Week Range | 680.00 - 1,198.00 |
| Beta | 1.19 |
| RSI | 52.87 |
| Earnings Date | Mar 27, 2026 |
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. [Read more]
News
Hopwood Financial Services, Inc. Sells 200 Shares of Oramed Pharmaceuticals Inc (ORMP)
Hopwood Financial Services, Inc. Sells 200 Shares of Oramed Pharmaceuticals Inc (ORMP)
Oramed To Transfer POD Technology To Lifeward; To Receive 49.9% Beneficial Ownership Interest
(RTTNews) - Oramed Pharmaceuticals Inc. (ORMP) and Lifeward Ltd. (LFWD) announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited invest...
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intend...
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while reta...
Oramed receives $18 million payment from Scilex, approves $0.25 per share dividend
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK , Jan. 7, 2026 /PRNewswire/ -- Oramed...
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed ...
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
Oramed (ORMP) Implements Stockholder Rights Agreement
Oramed (ORMP) Implements Stockholder Rights Agreement
Oramed Pharmaceuticals GAAP EPS of $1.26
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) ...
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 20...
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partners...
Oramed Pharmaceuticals (ORMP) Receives $13 Million from Scilex for Warrants
Oramed Pharmaceuticals (ORMP) Receives $13 Million from Scilex for Warrants
Oramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical
Oramed Pharmaceuticals (ORMP) has closed a strategic investment in Alpha Tau Medical (DRTS). Through a registered direct offering, an affiliate of Oramed purcha
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials a...
Oramed Pharmaceuticals Issues Letter to Shareholders
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of O...
Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock
A February filing shows that Representative Brad Knott reported a sale in Oramed Pharmaceuticals (NASDAQ: ORMP), valued between $15,001 and $50,000. The transaction date is listed as February 25, 202...
Oramed announces spinoff of protein drug technology
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a dir...
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery pla...
Oramed Letter to Shareholders
Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (...
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously ...